Provided by Tiger Trade Technology Pte. Ltd.

IX Biopharma

0.560
+0.0305.66%
Volume:15.92M
Turnover:8.76M
Market Cap:609.84M
PE:-67.47
High:0.565
Open:0.530
Low:0.525
Close:0.530
52wk High:0.625
52wk Low:0.076
Shares:1.09B
Float Shares:478.30M
Volume Ratio:2.96
T/O Rate:3.33%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-0.008
EPS(LYR):-0.008
ROE:-101.43%
ROA:-32.16%
PB:39.61
PE(LYR):-67.47

Loading ...

iX Biopharma outlines Wafermine milestones and cash runway ahead of Oct, 16 2026 AGM

SGX Filings
·
Oct 10

iX Biopharma Completes Debt Capitalization

MT Newswires
·
Oct 09

IX Biopharma Ltd. Proposed Debt Capitalisation - Completion of Issuance and Allotment

THOMSON REUTERS
·
Oct 09

iX Biopharma secures SGX nod for issuance of 2.68 million shares under debt deal

SGX Filings
·
Oct 08

iX Biopharma plans debt-for-equity swap worth about 1.51 million Singapore dollars

SGX Filings
·
Oct 05

Net Institutional Inflow Reversals into Late September

sgx.com
·
Sep 28

IX Biopharma Shareholder Anson Properties Cuts Stake to 4.99% from 5.08%

Reuters
·
Sep 10

US Declaration Clears Path for iX Biopharma Pain Drug; Shares Jump 13%

MT Newswires
·
Sep 07

SG Morning Call | Brokerages Lift Their STI Targets as Earnings Drive Momentum into Q4

TigerNews SG
·
Sep 07

iX Biopharma gains US emergency pathway for Wafermine acute pain drug

SGX Filings
·
Sep 07

IX Biopharma Ltd. Request for Lifting of Trading Halt - Sponsor's Statement

THOMSON REUTERS
·
Sep 07

IX Biopharma Seeks SGX-ST Trading Halt Lift for Shares in Singapore

Reuters
·
Sep 07

IX Biopharma Ltd - US Government Opens Emergency Pathway, Clears Path for Wafermine Application for Eua

THOMSON REUTERS
·
Sep 07

IX Biopharma Shares on SGX-ST Halted Pending Announcement

Reuters
·
Sep 04

IX Biopharma Ltd. Request for Trading Halt

THOMSON REUTERS
·
Sep 04

Singapore Shares Track Regional Losses Amid US-Iran Standoff; OUE Healthcare Surges 23%

MT Newswires
·
Aug 24

iX Biopharma's Net Loss Nearly Triples in Fiscal Q4; Shares Slump 9%

MT Newswires
·
Aug 24

iX Biopharma FY2026 revenue at S$6.85 million, net loss narrows to S$7.99 million on accelerating US demand

SGX Filings
·
Aug 21

IX Biopharma Ltd FY Revenue SGD 6.853 Million

THOMSON REUTERS
·
Aug 21

IX Biopharma Ltd FY Net Income SGD -7.993 Million

THOMSON REUTERS
·
Aug 21